Skip to main content
RecallRadar
FDAClass II

Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL (18 mg/mL), in GALAXY 50 mL Single… Recalled: CGMP Deviations

Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL (18… was recalled on August 6, 2026 in cooperation with the U.S. Food and Drug Administration because CGMP Deviations.

Is my unit affected?

Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL (18 mg/mL), in GALAXY 50 mL Single Dose Container, Rx only, Sterile Nonpyrogenic, Manufactured by: Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-4114-50.

Model, lot & date codes to check

Lot # NC194075, Exp Date: 10/29/2027.

Units affected: N/A

Where it was sold: US Nationwide; Puerto Rico; and Chile.

Compare the codes above against the label on your product — usually on the bottom, the back panel, or the packaging. If your unit isn't listed, it is not part of this recall.

What's the hazard?

CGMP Deviations

Class II means the product might cause a temporary or medically reversible health problem; the chance of serious harm is remote.

Your remedy & how to claim it

Stop using the product. Return it to the place of purchase for a refund, or dispose of it. Contact the recalling firm with questions.

Contact: Recalling firm: Baxter Healthcare Corporation

Not sure what you're entitled to? Read our guide: what to do if your product is recalled.

Official recall notice

Always confirm details on the official notice from the U.S. Food and Drug Administration before acting.

View official notice →

Get recall alerts

Be the first to know when products like this are recalled. Free weekly digest, unsubscribe anytime.

Double opt-in: we only email you after you confirm. No spam, ever.